AUAUniversity podcast

Player FM - Internet Radio Done Right

21 subscribers

تمت الإضافة منذ قبل six عام

المحتوى المقدم من AUAUniversity and American Urological Association. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة AUAUniversity and American Urological Association أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

State Secrets: Inside The Making Of The Electric State

1
Family Secrets: Chris Pratt & Millie Bobby Brown Share Stories From Set 22:08

منذ 26 يومًا22:08

التشغيل لاحقا

قوائم

إعجاب

احب

22:08

Host Francesca Amiker sits down with directors Joe and Anthony Russo, producer Angela Russo-Otstot, stars Millie Bobby Brown and Chris Pratt, and more to uncover how family was the key to building the emotional core of The Electric State . From the Russos’ own experiences growing up in a large Italian family to the film’s central relationship between Michelle and her robot brother Kid Cosmo, family relationships both on and off of the set were the key to bringing The Electric State to life. Listen to more from Netflix Podcasts . State Secrets: Inside the Making of The Electric State is produced by Netflix and Treefort Media.…

AUAUniversity

منزل السلاسل•Feed

The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org

378 حلقات

#Prostate Cancer #Men's Health #AUAUniversity #Health and Well-Being #Podcasting Education #American Urological Association

AUAUniversity

21 subscribers

updated منذ 9 ساعات

منزل السلاسل•Feed

The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org

378 حلقات

#Prostate Cancer #Men's Health #AUAUniversity #Health and Well-Being #Podcasting Education #American Urological Association

كل الحلقات

1
Update Series 2025: Congenitalism: Transitioning Patients with Congenital Urological Anomalies 25:58

منذ 9 hours25:58

25:58

Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care Setting Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care Setting Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25…

1
AUA2025: Masterclass: Renal Access and Interventions (2025) 30:05

منذ 22 يومًا30:05

30:05

AUA2025: Masterclass: Renal Access and Interventions (2025) Cohost: Rob Sweet, MD, FACS, MAMSE and Thomas Chi, MD, MBA Tune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Drs. Thomas Chi and Robert Sweet discuss Masterclass: Renal Access and Interventions, an all new interactive training offering skills in percutaneous renal access and image-guided renal interventions. Early Bird deadline for Hands-on Skills trainings has been EXTENDED - ends March 24. Spaces are limited – Register now!…

1
Hereditary Kidney Cancer Syndromes (Republished) 38:58

منذ 30 يومًا38:58

38:58

Hereditary Kidney Cancer Syndromes CME Available: https://auau.auanet.org/node/41772 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from: Merck & Co., Inc. LEARNING OBJECTIVES: At the conclusion of this activity, participants should be able to: 1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation. 2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members. 3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors. 4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies. 5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.…

1
AUA2025: Fundamentals of Prostate MRI and Transperineal Interventions (2025) 36:00

منذ 5 weeks36:00

36:00

AUA2025: Fundamentals of Prostate MRI and Transperineal Interventions (2025) Cohost: Arvin K. George, MD and James Wysock, MD, MSc Tune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Dr. Arvin K. George and Dr. James Wysock discuss optimizing diagnosis of clinically significant prostate cancer along with a preview of what practicing urologists will gain from attending Fundamentals of Prostate MRI and Transperinal Interventions. Among the skillsets of MRI interpretation, segmentation, fusion-guided transperineal prostate biopsy, and transperineal spacer techniques, attendees also receive access to a library of on-demand virtual didactics straight from the experts! Early Bird deadline for Hands-on Skills trainings ends March 7. Spaces are limited – Register now! https://www.auanet.org/AUA2025/register/hands-on-skills-trainings Outline: Segment #1: The Changing Landscape of Prostate Cancer Diagnostics Segment #2: Why Transperineal Biopsy? Segment #3: What Participants Will Learn - MRI Segment #4: What Participants Will Learn – Transperineal Techniques Segment #5: Why you should attend this course…

1
Recognition and Management of Complications Following Gender Affirming Surgery 41:30

منذ 6 weeks41:30

41:30

Recognition and Management of Complications Following Gender Affirming Surgery Co-Host: Laura Douglass, MD Outline: Segment #1 Topic: Why is this important for ALL urologists to know? Segment #2 Topic: Introduction to Gender Affirming Surgery (GAS) Segment #3 Topic: Emergency/ED consultations vs. Outpatient/clinic consultations Resources: - Hanley K, Wittenberg H, Gurjala D, Safir MH, Chen EH. Caring for Transgender Patients: Complications of Gender-Affirming Genital Surgeries. Ann Emerg Med. 2021 Sep;78(3):409-415. - Krakowsky Y, Shah G, Nguyen AV, Kavanagh AG, Potter E, Remondini T, Goldsher YW, Millman A. Gender-affirming care in urology: emergency care of the gender-affirming surgical patient-what the primary urologist needs to know. BJU Int. 2024 Feb;133(2):124-131. doi: 10.1111/bju.16249. Epub 2023 Dec 14. PMID: 38060336. - Mann RA, Kasabwala K, Kim N, Pariser JJ. The Management of Complications of Feminizing Gender Affirming Genital Surgery. Urology. 2021 Jun;152:67-73. doi: 10.1016/j.urology.2021.01.031. Epub 2021 Jan 23. PMID: 33493512. - Maffucci F, Clark J, Jun M, Douglass L. A Urologist's Guide to Caring for Transgender and Gender Diverse Patients. Urol Clin North Am. 2023 Nov;50(4):577-585. doi: 10.1016/j.ucl.2023.06.020. Epub 2023 Aug 9. PMID: 37775216. - Nikolavsky D, Hughes M, Zhao LC. Urologic Complications After Phalloplasty or Metoidioplasty. Clin Plast Surg. 2018 Jul;45(3):425-435. doi: 10.1016/j.cps.2018.03.013. PMID: 29908632.…

1
AUA Guidelines: Diagnosis and Treatment of Infertility in Men 38:08

منذ 7 weeks38:08

38:08

AUA Guidelines: Diagnosis and Treatment of Infertility in Men Co-Host: Robert E. Brannigan, MD Outline: Segment #1 Topic: New Table 1 Reviewing “Common Terms” in Semen Analysis and Update to the WHO Semen Analysis Reference Ranges Segment #2 Update to the WHO Semen Analysis Reference Ranges Segment #3 Topic: Y Chromosome Microdeletion Testing Change in Testing Guidance Segment #4 Topic: Pelvic MRI imaging is an option for men with suspected ejaculatory duct obstruction Segment #5 Topic: For couples with recurrent pregnancy loss, clinicians should evaluate the male partner with karyotype (Expert Opinion) and sperm DNA fragmentation Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Brannigan RE, Hermanson L, Kaczmarek J, Kim SK, Kirkby E, Tanrikut C. Updates to male infertility: AUA/ASRM guideline (2024). J Urol. Published online August 15, 2024. doi:10.1097/JU.0000000000004180. https://www.auajournals.org/doi/10.1097/JU.0000000000004180…

1
AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive Bladder 42:30

منذ 8 weeks42:30

42:30

AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive Bladder Co-Host: Anne Pelletier Cameron, MD, FRCSC, URPS Segment #1: Is this an update to the prior Guideline? Segment #2: What is new in the Diagnosis, ntitial Assessment and Initial Management of OAB? Segment#3: What does the Guideline say about Oral Medication? Segment #4: What's new in minimally invasive prodcedures Segment #5: UDS and Cystoscopy Segment #6: What is new and exciting on the horizion for OAB Segment #7: Where to start and the most impactpact research in this area The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. Published online April 23, 2024. doi:10.1097/JU.0000000000003985. https://www.auajournals.org/doi/10.1097/JU.0000000000003985…

1
AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer 35:22

منذ 9 weeks35:22

35:22

AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer Guest: Jeffrey M Holzbeierlein, MD Outline: Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant cisplatin based chemotherapy or adjuvant immunotherapy. Segment #2: Guideline Statement 11-When performing a cystectomy in males the bladder, prostate cand seminal vesicles should be removed (no change) but in females clinicians should consider removal of adjacent reproductive organs based on individual disease characteristics and need to obtain negative margins. Organ sparing procedures in females should be considered based on disease location and characteristics on an individual basis. Segment #3: Guideline Statement 20-When performing bilateral pelvic lymphadenectomy , clinicians should remove, at a minimum, the external and internal iliac and obturator lymph nodes (standard lymphadenectomy). Segment #4: Future Directions Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO guideline (2017; amended 2020, 2024). J Urol. Published online April 25, 2024. doi:10.1097/JU.0000000000003981 https://www.auajournals.org/doi/10.1097/JU.0000000000003981…

1
Biomarkers and Molecular Imaging for Prostate Cancer (Republished) 33:29

منذ 10 weeks33:29

33:29

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.…

1
Appropriate Use of Genetic Testing (Republished) 38:07

منذ 11 weeks38:07

38:07

Appropriate Use of Genetic Testing (who, what, when and how?) CME Available: auau.auanet.org/node/41734 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications. 2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration. 3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.…

1
Treatment Intensification in Metastatic HSPC (Republished) 41:26

منذ 12 weeks41:26

41:26

Treatment Intensification in Metastatic HSPC CME Available: https://auau.auanet.org/node/41733 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.…

1
Sequencing Of Agents (Republished) 32:55

منذ 13 weeks32:55

32:55

Sequencing Of Agents CME Available: auau.auanet.org/node/41735 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials. 3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance. 4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.…

1
Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists 1:14:46

منذ 15 weeks1:14:46

1:14:46

Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41961 After participating in this CME activity, participants will be able to: 1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions. 2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. 3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC. 4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies. 5. Properly manage adverse events associated with NMIBC treatment. Acknowledgements Support provided by an independent educational grant from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc.…

منذ 25 weeks38:58

38:58

AUAUniversity

1
Prostate Cancer Update (2024): Expert Guidance for Urologists 1:18:55

منذ 27 weeks1:18:55

1:18:55

Prostate Cancer Update (2024): Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41868 Acknowledgements Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc. Learning Objectives At the conclusion of this activity, the learner will: 1. Align their practice with current AUA Guidelines (and recent amendments) pertaining to Screening, Diagnosis, and Management of Prostate Cancer. 2. Determine appropriate use of biomarker testing as it relates to diagnosis and therapy. 3. Analyze the role of imaging and types of imaging that aid in staging patients with prostate cancer. 4. Implement appropriate treatment paradigms for metastatic prostate cancer including treatment intensification. 5. Discuss the role of genetic and molecular profiling in the personalization of prostate cancer treatment plans.…

AUAUniversity

منذ 33 weeks1:41:21

1:41:21

How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent CME Available: https://auau.auanet.org/node/41124 At the conclusion of this activity, participants will be able to: 1. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease. 2. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings. 3. Apply the findings of PSMA PET/CT for the best individual therapeutic approach. 4. Identify patients with radiorecurrent organ-confined prostate cancer. 5. Identify those patients who are candidates for local therapy of oligometastatic disease in relapsing prostate cancer. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.